比较雷珠单抗和贝伐珠单抗对新生血管AMD的疗效(英文) 被引量：2

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration

下载PDF

导出

摘要目的:比较玻璃体内注射雷珠单抗与贝伐珠单抗对年龄相关性黄斑变性(age-related macular degeneration,AMD)的疗效,治疗方案必要时采用。方法:回顾性分析63例63眼(雷珠单抗治疗组35眼,贝伐珠单抗治疗组28眼)新确诊新生血管年龄相关性黄斑变性患者的资料。治疗12mo后随访,分析比较两组患者的最佳矫正视力(BCVA)和黄斑中心凹厚度(CFT)。采用双尾t检验和单因素方差分析比较两组最佳矫正视力和黄斑中心凹厚度的变化。结果:雷珠单抗治疗组35眼和贝伐珠单抗治疗组28眼均完成12mo随访,并记录数据。雷珠单抗治疗组最佳矫正视力均值增加0.1logMAR;相反,贝伐珠单抗治疗组最佳矫正视力均值下降0.06logMAR(P=0.01)。雷珠单抗治疗组13眼(37%)和贝伐珠单抗治疗组4眼(14%)最佳矫正视力至少增加0.3logMAR。雷珠单抗治疗组平均黄斑中心凹厚度减少41.6μm,贝伐珠单抗治疗组减少8.1μm(P=0.003)。两组平均注射次数是4.46次和4.11次(P>0.05)。结论:玻璃体内注射雷珠单抗组在视力和消水肿方面疗效优于贝伐珠单抗组。但是,两种药的疗效和安全性还需要随机的长期临床试验来验证。 AIM：To compare the efficacy of intravitreal ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration （AMD） using a pro re nata （ PRN） treatment regimen. METHODS： A total of 63 eyes （ 35 eyes treated with ranibizumab and 28 eyes treated with bevacizumab） of 63 patients with newly diagnosed neovascular AMD were analyzed and compared retrospectively. Outcomes included comparison of best - corrected visual acuity （ BCVA ） and central foveal thickness （ CFT ） after ranibizumab or bevacizumab treatment at 12mo follow-up. Two-tailed t-tests and one-way ANOVA were used to compare mean changes in BCVA and CFT for different groups. RESULTS： Thirty-five eyes treated with ranibizumab and 28 eyes treated with bevacizumab were enrolled and completed 12mo follow - up. At 12mo, mean BCVA increased by 0. 1logMAR with ranibizumab treatment;however BCVA decreased by 0. 06logMAR with bevacizumab treatment （P= 0. 01）. A gain of at least 0.3logMAR in BCVA was observed in 13 eyes （ 37%） treated with ranibizumab and in 4 eyes （ 14%） treated with bevacizumab. Mean CFT reduced by 41. 6μm and 8. 1μm in the ranibizumab and bevacizumab groups, respectively （P=0. 003）. The mean number of injections per eye was 4. 46 with ranibizumab and 4. 11 with bevacizumab （P〈0. 05）. CONCLUSION： Intravitreal ranibizumab yielded better visual and anatomical results than bevacizumab. However, randomized long-term clinical trials are needed to draw conclusions about efficacy and safety of the two drugs.

作者 Huseyin Serdarogullari Muzaffer Ozturk Umur Kayhan Selim Bolukbasi Burak Erden Mustafa Elcioglu

机构地区奥克梅达尼教学研究医院眼科顿尼亚Goz Hastanesi世界眼科医院

出处《国际眼科杂志》 CAS 2014年第5期797-801,共5页 International Eye Science

关键词年龄相关性黄斑变性抗血管内皮生长因子治疗雷珠单抗贝伐珠单抗脉络膜新生血管 age-related macular degeneration anti-VEGF therapy ranibizumab bevacizumab choroidal neovascularization

分类号 R774.5 [医药卫生—眼科]

引文网络
相关文献

参考文献33

1Bressler NM, Bressler SB, Congdon NG, Ferris FL B, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM, Age- Related Eye Disease Study Research Group. Potential public health impact of Age- Related Eye Disease Study results: AREDS report no 11. Arch Ophthalmol 2003 ,121 ( 11 ) :1621-1624.
2Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age- related macular degeneration. Am J Ophthalmol 2004 , 137 ( 3 ) :486-495.
3Congdon N, O'Colmain B, Klaver CC, Klein R, Mufioz B, Friedman DS, Kempen J, Taylor HR, Mitchell P, Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004,122(4) :477-485.
4Friedman DS, O'Colmain BJ, Mufioz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J, Eye Diseases Prevalence Research Group. Prevalence of age-related maeular degeneration in the United States. Arch Ophthalmol 2004 , 122 (4) : 564 -572.
5Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, de Jong PT. The prevalence of age- related maculopathy in the Rotterdam Study. Ophthalmology 1995 ,102(2) :205-210.
6Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977 , 106 ( 1 ) : 17-32.
7Foran S, Wang JJ, Mitchell P. Causes of visual impairment in two older population cross- sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003,10(4) :215-225.
8Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY , MARINA Study Group. Ranibizumab for neovaseular age- related macular degeneration. N Engl J Med 2006 , 355 ( 14 ) : 1419 - 1431.
9Spaide RF,Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age- related macular degeneration. Retina 2006 ,26(4) :383-390.
10Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005 ,36(4) :331-335.